[go: up one dir, main page]

WO2010013498A1 - 変形性関節症治療剤又は予防剤 - Google Patents

変形性関節症治療剤又は予防剤 Download PDF

Info

Publication number
WO2010013498A1
WO2010013498A1 PCT/JP2009/003668 JP2009003668W WO2010013498A1 WO 2010013498 A1 WO2010013498 A1 WO 2010013498A1 JP 2009003668 W JP2009003668 W JP 2009003668W WO 2010013498 A1 WO2010013498 A1 WO 2010013498A1
Authority
WO
WIPO (PCT)
Prior art keywords
osteoarthritis
agent
igm
finding
type anti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2009/003668
Other languages
English (en)
French (fr)
Inventor
西岡久寿樹
遊道和雄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Argenes
Argenes Inc
St Marianna University School of Medicine
Original Assignee
Argenes
Argenes Inc
St Marianna University School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argenes, Argenes Inc, St Marianna University School of Medicine filed Critical Argenes
Priority to CA2732715A priority Critical patent/CA2732715C/en
Priority to CN200980138584.6A priority patent/CN102170905B/zh
Priority to BRPI0917554A priority patent/BRPI0917554A2/pt
Priority to RU2011107405/15A priority patent/RU2492871C2/ru
Priority to AU2009277824A priority patent/AU2009277824B2/en
Priority to KR1020117004979A priority patent/KR101196514B1/ko
Priority to JP2009548250A priority patent/JP4560822B2/ja
Priority to US13/056,730 priority patent/US8377444B2/en
Priority to EP09802743.6A priority patent/EP2322220B1/en
Publication of WO2010013498A1 publication Critical patent/WO2010013498A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

　【課題】　本発明は，変形性関節症，及び変形性関節症性関節炎（滑膜炎）に対する治療剤及び予防剤を提供することを目的とする。 　【解決手段】　　本発明は，ＩｇＭ型抗Ｆａｓ抗体を用いることで，変形性関節症の症状を緩和することができるという知見に基づくものである。具体的には，本発明は，ＩｇＭ型抗Ｆａｓ抗体を用いることで，軟骨基質分解酵素産生を抑制することができるという知見に基づくものである。また，本発明は，ＩｇＭ型抗Ｆａｓ抗体を用いることで，軟骨基質産生能を改善できるという知見に基づくものである。 　
PCT/JP2009/003668 2008-08-01 2009-07-31 変形性関節症治療剤又は予防剤 Ceased WO2010013498A1 (ja)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA2732715A CA2732715C (en) 2008-08-01 2009-07-31 Treatment agent or preventative agent for osteoarthritis
CN200980138584.6A CN102170905B (zh) 2008-08-01 2009-07-31 骨关节炎治疗剂及预防剂
BRPI0917554A BRPI0917554A2 (pt) 2008-08-01 2009-07-31 agente de tratamento ou agente de prevenção para oesteoartrite
RU2011107405/15A RU2492871C2 (ru) 2008-08-01 2009-07-31 Терапевтическое или профилактическое средство для лечения остеоартрита
AU2009277824A AU2009277824B2 (en) 2008-08-01 2009-07-31 Therapeutic agent or preventive agent for osteoarthritis
KR1020117004979A KR101196514B1 (ko) 2008-08-01 2009-07-31 변형성 관절증 치료제 또는 예방제
JP2009548250A JP4560822B2 (ja) 2008-08-01 2009-07-31 変形性関節症治療剤又は予防剤
US13/056,730 US8377444B2 (en) 2008-08-01 2009-07-31 Therapeutic agent or preventive agent for osteoarthritis
EP09802743.6A EP2322220B1 (en) 2008-08-01 2009-07-31 Therapeutic agent or preventive agent for osteoarthritis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008-199232 2008-08-01
JP2008199232 2008-08-01

Publications (1)

Publication Number Publication Date
WO2010013498A1 true WO2010013498A1 (ja) 2010-02-04

Family

ID=41610208

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2009/003668 Ceased WO2010013498A1 (ja) 2008-08-01 2009-07-31 変形性関節症治療剤又は予防剤

Country Status (10)

Country Link
US (1) US8377444B2 (ja)
EP (1) EP2322220B1 (ja)
JP (1) JP4560822B2 (ja)
KR (1) KR101196514B1 (ja)
CN (2) CN102170905B (ja)
AU (1) AU2009277824B2 (ja)
BR (1) BRPI0917554A2 (ja)
CA (1) CA2732715C (ja)
RU (1) RU2492871C2 (ja)
WO (1) WO2010013498A1 (ja)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011093083A1 (ja) * 2010-01-29 2011-08-04 Ａｘｉｓ株式会社 変形性関節症治療又は予防用医薬組成物及びその製造方法
WO2011093081A1 (ja) * 2010-01-29 2011-08-04 Ａｘｉｓ株式会社 変形性関節症治療剤を含有する注射剤
WO2011093082A1 (ja) * 2010-01-29 2011-08-04 Ａｘｉｓ株式会社 変形性関節症治療剤または予防剤を製造するための使用
WO2012043634A1 (ja) * 2010-09-29 2012-04-05 株式会社エヌビィー健康研究所 ヒトプロスタグランジンｅ２受容体ｅｐ４に対する抗体
JP2012219022A (ja) * 2011-04-05 2012-11-12 Mss:Kk 抗体を有効成分として含む血友病の治療剤
US10689449B2 (en) 2015-01-20 2020-06-23 Igm Biosciences, Inc. Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2582974C1 (ru) * 2015-06-01 2016-04-27 Федеральное бюджетное учреждение "Государственный институт лекарственных средств и надлежащих правил" (ФБУ "ГИЛС и НП") Комбинированная активная композиция для лечения заболеваний опорно-двигательного аппарата

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07194384A (ja) 1983-04-08 1995-08-01 Genentech Inc 免疫グロブリンｄｎａ含有発現ベクター及び組換え宿主細胞
JPH0840897A (ja) 1994-07-06 1996-02-13 Eli Lilly & Co 骨損失の抑制用医薬組成物
JPH10146194A (ja) 1990-01-12 1998-06-02 Abjenics Inc 異種抗体の生成
JP2828340B2 (ja) 1988-12-28 1998-11-25 プロテイン デザイン ラブス，インコーポレイティド ＩＬ―２レセプターのｐ５５ Ｔａｃタンパク質に特異的なキメラ免疫グロブリン
JP2004059582A (ja) 2002-06-07 2004-02-26 Sankyo Co Ltd 骨破壊の治療または予防剤組成物の併用効果
WO2004017996A1 (ja) 2002-08-20 2004-03-04 Yamanouchi Pharmaceutical Co., Ltd. 関節軟骨細胞外マトリクス分解阻害剤
JP2005034154A (ja) 2003-07-16 2005-02-10 Ccl Holdings Co Ltd 完全ヒト抗体の調製
JP2006151843A (ja) 2004-11-26 2006-06-15 Shimada Kagaku Kogyo Kk カテプシンｋ阻害剤およびその機能が付与された食品
JP2007000141A (ja) 2005-05-25 2007-01-11 Tokyo Univ Of Science 完全ヒト抗体産生ハイブリドーマの作製方法、及び融合ミエローマ細胞
JP2007051077A (ja) 2005-08-17 2007-03-01 Nippon Barrier Free:Kk 変形性関節症の予防及び治療用組成物
JP2007537134A (ja) 2003-07-18 2007-12-20 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 関節病を治療するためのｐａｋ阻害剤の使用
JP2008516593A (ja) 2004-10-15 2008-05-22 ガラパゴス・ナムローゼ・フェンノートシャップ 関節変性疾患及び炎症性疾患の治療に有用な分子標的及び化合物、並びにそれらの同定方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3023237C2 (de) * 1980-06-21 1983-03-10 Smit Ovens Nijmegen B.V., Nijmegen Vorrichtung zum Induktionslöten von aus dünnwandigen Rohren bestehenden Rahmenkonstruktionen, insbesondere Zweiradrahmen
CA2158822C (en) * 1994-09-27 2008-12-23 Kusuki Nishioka Therapeutic agent for rheumatic disease
CN1203922A (zh) * 1997-03-21 1999-01-06 三共株式会社 人源化抗人fas抗体
AU734758B2 (en) * 1997-04-01 2001-06-21 Sankyo Company Limited Anti-fas antibodies
US6927044B2 (en) * 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
AU761544C (en) * 1999-05-24 2004-02-12 Sankyo Company Limited Medicinal compositions containing anti-Fas antibody
DE10034607A1 (de) * 2000-07-20 2002-02-07 Gundram Jung Multispezifisches Reagenz zur selektiven Stimulierung von Zelloberflächenrezeptoren
US6600057B2 (en) * 2000-12-29 2003-07-29 Kimberly-Clark Worldwide, Inc. Matrix metalloproteinase inhibitors
PE20030340A1 (es) * 2001-08-28 2003-04-05 Sankyo Co Metodo para el tratamiento o prevencion de desgaste oseo
AU2003242265A1 (en) * 2002-06-07 2003-12-22 Sankyo Company, Limited Combined effects of therapeutic or preventive agent composition for bone breakage
JP2004277311A (ja) * 2003-03-14 2004-10-07 Wakunaga Pharmaceut Co Ltd 新規ｍｍｐ−３阻害剤
GB0327493D0 (en) * 2003-11-26 2003-12-31 Univ Belfast Treatment medicament
JP2007512369A (ja) * 2003-11-26 2007-05-17 エンテロス・インコーポレーテッド 低酸素誘導因子１αアンタゴニストを用いる慢性関節リウマチの処置
US7510710B2 (en) * 2004-01-08 2009-03-31 The Regents Of The University Of Colorado Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor
US7445794B1 (en) * 2004-04-29 2008-11-04 The Regents Of The University Of Colorado Methods for treating human proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors
RU2298410C1 (ru) * 2005-09-12 2007-05-10 ЗАО "РеМеТэкс" Биотрансплантат и способ лечения ревматических и аутоиммунных заболеваний
JP2007204398A (ja) * 2006-01-31 2007-08-16 Ｔｏｗａ Ｃｏｒｐｏｒａｔｉｏｎ 株式会社 脂肪分解促進作用組成物、ｃＡＭＰ−ＰＤＥ活性阻害作用組成物、ヘキソサミニダーゼ遊離抑制作用組成物、ＭＭＰ−１活性阻害作用組成物、コラーゲン産生促進組成物、皮膚線維芽細胞増殖作用組成物、エストロゲン様作用組成物、テストステロン５α−リダクターゼ活性阻害作用組成物、抗老化作用組成物、育毛作用組成物、美白作用組成物および抗炎症作用組成物

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07194384A (ja) 1983-04-08 1995-08-01 Genentech Inc 免疫グロブリンｄｎａ含有発現ベクター及び組換え宿主細胞
JP2828340B2 (ja) 1988-12-28 1998-11-25 プロテイン デザイン ラブス，インコーポレイティド ＩＬ―２レセプターのｐ５５ Ｔａｃタンパク質に特異的なキメラ免疫グロブリン
JPH10146194A (ja) 1990-01-12 1998-06-02 Abjenics Inc 異種抗体の生成
JPH10155492A (ja) 1990-01-12 1998-06-16 Abjenics Inc 異種抗体の生成
JPH0840897A (ja) 1994-07-06 1996-02-13 Eli Lilly & Co 骨損失の抑制用医薬組成物
JP2004059582A (ja) 2002-06-07 2004-02-26 Sankyo Co Ltd 骨破壊の治療または予防剤組成物の併用効果
WO2004017996A1 (ja) 2002-08-20 2004-03-04 Yamanouchi Pharmaceutical Co., Ltd. 関節軟骨細胞外マトリクス分解阻害剤
JP2005034154A (ja) 2003-07-16 2005-02-10 Ccl Holdings Co Ltd 完全ヒト抗体の調製
JP2007537134A (ja) 2003-07-18 2007-12-20 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 関節病を治療するためのｐａｋ阻害剤の使用
JP2008516593A (ja) 2004-10-15 2008-05-22 ガラパゴス・ナムローゼ・フェンノートシャップ 関節変性疾患及び炎症性疾患の治療に有用な分子標的及び化合物、並びにそれらの同定方法
JP2006151843A (ja) 2004-11-26 2006-06-15 Shimada Kagaku Kogyo Kk カテプシンｋ阻害剤およびその機能が付与された食品
JP2007000141A (ja) 2005-05-25 2007-01-11 Tokyo Univ Of Science 完全ヒト抗体産生ハイブリドーマの作製方法、及び融合ミエローマ細胞
JP2007051077A (ja) 2005-08-17 2007-03-01 Nippon Barrier Free:Kk 変形性関節症の予防及び治療用組成物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AKIRA FUKUDA ET AL.: "Henkeisei Kansetsusho Kenkyu no Genjo OA to Hakotsu Saibo - OA Chiryoyaku no Aratana Target", SHUKAN IGAKU NO AYUMI, vol. 211, no. 4, 2004, pages 285 - 288, XP008142967 *
ARTHRITIS RHEUM, vol. 44, no. 8, 2001, pages 1800 - 1807
NAKAJIMA ET AL.: "APOPTOSIS AND FUNCTIONAL FAS ANTIGEN IN RHEUMATOID ARTHRITIS SYNOVICYTES", ARTHRITIS & RHEUMATISM, vol. 38, no. 4, 1995, pages 485 - 491
See also references of EP2322220A4

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5792636B2 (ja) * 2010-01-29 2015-10-14 Ａｘｉｓ株式会社 変形性関節症治療剤を含有する注射剤
WO2011093081A1 (ja) * 2010-01-29 2011-08-04 Ａｘｉｓ株式会社 変形性関節症治療剤を含有する注射剤
WO2011093082A1 (ja) * 2010-01-29 2011-08-04 Ａｘｉｓ株式会社 変形性関節症治療剤または予防剤を製造するための使用
WO2011093083A1 (ja) * 2010-01-29 2011-08-04 Ａｘｉｓ株式会社 変形性関節症治療又は予防用医薬組成物及びその製造方法
US9200077B2 (en) 2010-01-29 2015-12-01 Axis, Inc. Injectable solution containing therapeutic agent for osteoarthritis
WO2012043634A1 (ja) * 2010-09-29 2012-04-05 株式会社エヌビィー健康研究所 ヒトプロスタグランジンｅ２受容体ｅｐ４に対する抗体
JP5273689B2 (ja) * 2010-09-29 2013-08-28 株式会社エヌビィー健康研究所 ヒトプロスタグランジンｅ２受容体ｅｐ４に対する抗体
US9175080B2 (en) 2010-09-29 2015-11-03 Nb Health Laboratory Co., Ltd. Antibody against human prostaglandin E2 receptor EP4
US10435465B2 (en) 2010-09-29 2019-10-08 Nb Health Laboratory Co. Ltd. Antibody against human prostaglandin E2 receptor EP4
US11649281B2 (en) 2010-09-29 2023-05-16 Nb Health Laboratory Co., Ltd. Antibody against human prostaglandin E2 receptor EP4
JP2012219022A (ja) * 2011-04-05 2012-11-12 Mss:Kk 抗体を有効成分として含む血友病の治療剤
US10689449B2 (en) 2015-01-20 2020-06-23 Igm Biosciences, Inc. Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof
US11578131B2 (en) 2015-01-20 2023-02-14 Igm Biosciences, Inc. Polynucleotides encoding death domain-containing receptor-5 (DR5) binding molecules

Also Published As

Publication number Publication date
CN105169389A (zh) 2015-12-23
CN102170905A (zh) 2011-08-31
KR20110094267A (ko) 2011-08-23
BRPI0917554A2 (pt) 2017-06-20
CA2732715C (en) 2015-04-07
CA2732715A1 (en) 2010-02-04
US8377444B2 (en) 2013-02-19
RU2011107405A (ru) 2012-09-10
RU2492871C2 (ru) 2013-09-20
KR101196514B1 (ko) 2012-11-01
EP2322220A1 (en) 2011-05-18
US20110182915A1 (en) 2011-07-28
JPWO2010013498A1 (ja) 2012-01-05
AU2009277824B2 (en) 2013-06-06
CN102170905B (zh) 2016-08-03
EP2322220B1 (en) 2014-01-01
JP4560822B2 (ja) 2010-10-13
AU2009277824A1 (en) 2010-02-04
EP2322220A4 (en) 2012-08-29

Similar Documents

Publication Publication Date Title
WO2010013498A1 (ja) 変形性関節症治療剤又は予防剤
WO2008124229A3 (en) Improved bioreactor surfaces
WO2007130560A3 (en) Solvent tolerant microorganisms and methods of isolation
WO2008089168A3 (en) Plasma immersion chamber
WO2009100102A3 (en) Ts23 alpha-amylase variants with altered properties
WO2011041584A3 (en) Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products
WO2008013996A3 (en) Engineered microorganisms for increasing product yield in biotransformations, related methods and systems
WO2009108860A8 (en) Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders
WO2008073406A3 (en) Solvent tolerant microorganisms
WO2009124330A3 (de) Behandlung von tumorerkrankungen
WO2010053519A3 (en) Alignment for edge field nano-imprinting
WO2008070268A3 (en) Pharmaceutical compositions
MY174318A (en) Enzymatic degradation of biomass substrates comprising mannan
WO2008066784A3 (en) Expression of foxp3 by cancer cells
PL2772543T3 (pl) Enzymatyczny proces wytwarzania beta-santalenu i odpowiadającego mu enzymu
IN2012DN01968A (ja)
WO2008013990A3 (en) Processes for the synthesis of o-desmethylvenlafaxine
WO2008075205A3 (en) Improved process for the preparation of voriconazole
WO2008051860A3 (en) Anodization
WO2010112462A3 (de) Kapselungsgehäusereduzierstück
WO2009076948A3 (de) Reduktone zur erzeugung von biogas
WO2012006355A3 (en) Dual stage active pixel devices and related methods
WO2009153047A3 (de) Biotechnologische herstellung von acrylsäure
WO2009101199A3 (en) Treatment of acne vulgaris; rosacea and rhinophym
EP2184104A4 (en) Catalyst for the production of hydrogen at low temperature, process for production of the catalyst, and process for production of hydrogen

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980138584.6

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2009548250

Country of ref document: JP

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09802743

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2732715

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 713/CHENP/2011

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009277824

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2011107405

Country of ref document: RU

Ref document number: 2009802743

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20117004979

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2009277824

Country of ref document: AU

Date of ref document: 20090731

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13056730

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0917554

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110201